Abstract
Many tumors express one or more proteins that are either absent or hardly present in normal tissues, and which can be targeted by radiopharmaceuticals for either visualization of tumor cells or for targeted therapy. Radiopharmaceuticals can consist of a radionuclide and a carrier molecule that interacts with the tumor target and as such guides the attached radionuclide to the right spot. Radiopharmaceuticals hold great promise for the future of oncology by providing early, precise diagnosis and better, personalized treatment. Most advanced developments with marketed products are based on whole antibodies or antibody fragments as carrier molecules. However, a substantial number of (pre)clinical studies indicate that radiopharmaceuticals based on other carrier molecules, such as peptides, nonimmunoglobulin scaffolds, or nucleic acids may be valuable alternatives. In this review, we discuss the biological molecules that can deliver radionuclide payloads to tumor cells in terms of their structure, the selection procedure, their (pre)clinical status, and advantages or obstacles to their use in a radiopharmaceutical design. We also consider the plethora of molecular targets existing on cancer cells that can be targeted by radiopharmaceuticals, as well as how to select a radionuclide for a given diagnostic or therapeutic product.
Keywords: Radiopharmaceuticals, molecular imaging, targeted therapy, antibody, peptides, non-immunoglobulin scaffolds, nucleic acids.
Current Pharmaceutical Design
Title:Biological Carrier Molecules of Radiopharmaceuticals for Molecular Cancer Imaging and Targeted Cancer Therapy
Volume: 20 Issue: 32
Author(s): A. Aerts, N.R.E.N. Impens, M. Gijs, M. D'Huyvetter, H. Vanmarcke, B. Ponsard, T. Lahoutte, A. Luxen and S. Baatout
Affiliation:
Keywords: Radiopharmaceuticals, molecular imaging, targeted therapy, antibody, peptides, non-immunoglobulin scaffolds, nucleic acids.
Abstract: Many tumors express one or more proteins that are either absent or hardly present in normal tissues, and which can be targeted by radiopharmaceuticals for either visualization of tumor cells or for targeted therapy. Radiopharmaceuticals can consist of a radionuclide and a carrier molecule that interacts with the tumor target and as such guides the attached radionuclide to the right spot. Radiopharmaceuticals hold great promise for the future of oncology by providing early, precise diagnosis and better, personalized treatment. Most advanced developments with marketed products are based on whole antibodies or antibody fragments as carrier molecules. However, a substantial number of (pre)clinical studies indicate that radiopharmaceuticals based on other carrier molecules, such as peptides, nonimmunoglobulin scaffolds, or nucleic acids may be valuable alternatives. In this review, we discuss the biological molecules that can deliver radionuclide payloads to tumor cells in terms of their structure, the selection procedure, their (pre)clinical status, and advantages or obstacles to their use in a radiopharmaceutical design. We also consider the plethora of molecular targets existing on cancer cells that can be targeted by radiopharmaceuticals, as well as how to select a radionuclide for a given diagnostic or therapeutic product.
Export Options
About this article
Cite this article as:
Aerts A., Impens N.R.E.N., Gijs M., D'Huyvetter M., Vanmarcke H., Ponsard B., Lahoutte T., Luxen A. and Baatout S., Biological Carrier Molecules of Radiopharmaceuticals for Molecular Cancer Imaging and Targeted Cancer Therapy, Current Pharmaceutical Design 2014; 20 (32) . https://dx.doi.org/10.2174/1381612819666140110114902
DOI https://dx.doi.org/10.2174/1381612819666140110114902 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Recent Patents in Pulmonary Delivery of Macromolecules
Recent Patents on Drug Delivery & Formulation Quantitative Analysis of Microbial Metabolism in the Human Large Intestine
Current Nutrition & Food Science Pharmacological and Biological Therapies for Metabolic Bone Disease in Critical Illness: An Integrative Physiology Approach
Current Drug Therapy A Comparative Study Among Various Statistical Tests Using Microarray Gene Expression Data
Current Bioinformatics Telomerase-Dependent Gene Therapy
Current Molecular Medicine Current and Emerging Therapies in Neuroendocrine Tumors: Impact of Genetic Targets on Clinical Outcomes
Clinical Cancer Drugs Meet Our Editorial Board Member
The Natural Products Journal First Inhibitors of the Steroidogenic Enzyme Type 7 17β-Hydroxysteroid Dehydrogenase
Letters in Drug Design & Discovery Involvement of Potassium and Chloride Channels and Other Transporters in Volume Regulation by Spermatozoa
Current Pharmaceutical Design Pharmacogenetics of Non-small Cell Lung Cancer (NSCLC): Time to "Work it Out"?
Current Pharmaceutical Design Human Genetic Variation: A Foundation for Rational Diagnosis and Individualized Treatment of Lung Cancer
Current Pharmacogenomics and Personalized Medicine Lipids as Activators of Innate Immunity in Peptide Vaccine Delivery
Current Medicinal Chemistry Antitumor Activity of Oxali-Titanocene Y in Xenografted CAKI-1 Tumors in Mice
Letters in Drug Design & Discovery Synthesis of New and Known Dicoumarols in Aqueous Media: A Green and Convenient Procedure Promoted by Titanium(IV) Oxide Nanoparticles
Letters in Organic Chemistry Cancer and Phase II Drug-Metabolizing Enzymes
Current Drug Metabolism Tamarix articulata (T. articulata) - An Important Halophytic Medicinal Plant with Potential Pharmacological Properties
Current Pharmaceutical Biotechnology Synthesis of Phosphorylated Derivatives of 2', 3'-O-Isopropylidene Adenosine and their In Ovo Antiviral Activity
Letters in Drug Design & Discovery The Mechanism of Calcitriol in Cancer Prevention and Treatment
Current Medicinal Chemistry Nanosuspensions of Poorly Water Soluble Drugs Prepared by Top-down Technologies
Current Pharmaceutical Design Electro-Organic Synthesis of New Esculetin Derivatives Based on 1,6-Conjugate Addition
Current Organic Chemistry